

Arwa Younis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3585707/publications.pdf>

Version: 2024-02-01

59
papers

898
citations

933447

10
h-index

552781

26
g-index

61
all docs

61
docs citations

61
times ranked

1043
citing authors

#	ARTICLE	IF	CITATIONS
1	Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1682-1690.	1.8	265
2	Global, regional, and national burden of ischaemic heart disease and its attributable risk factors, 1990â€“2017: results from the Global Burden of Disease Study 2017. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 50-60.	4.0	154
3	Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. <i>European Heart Journal</i> , 2021, 42, 1676-1684.	2.2	61
4	Worldwide Trends in Prevalence, Mortality, and Disability-Adjusted Life Years for Hypertensive Heart Disease From 1990 to 2017. <i>Hypertension</i> , 2021, 77, 1223-1233.	2.7	47
5	Metabolic syndrome is independently associated with increased 20-year mortality in patients with stable coronary artery disease. <i>Cardiovascular Diabetology</i> , 2016, 15, 149.	6.8	42
6	Pulsed-Field Ablation in Ventricular Myocardium Using a Focal Catheter. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e010375.	4.8	34
7	Relation of Neutrophil to Lymphocyte Ratio to Risk of Incident Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019, 123, 396-401.	1.6	25
8	The addition of vildagliptin to metformin prevents the elevation of interleukin 1ÃŸ in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study. <i>Cardiovascular Diabetology</i> , 2017, 16, 69.	6.8	23
9	The role and outcome of cardiac rehabilitation program in patients with atrial fibrillation. <i>Clinical Cardiology</i> , 2018, 41, 1170-1176.	1.8	23
10	Global, Regional, and National Burden of Myocarditis and Cardiomyopathy, 1990â€“2017. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 610989.	2.4	14
11	Big Data in Cardiology: State-of-Art and Future Prospects. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 844296.	2.4	12
12	Impaired Fasting Glucose Is the Major Determinant of the 20â€“Year Mortality Risk Associated With Metabolic Syndrome in Nondiabetic Patients With Stable Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	11
13	Trends and Regional Variation in Prevalence of Cardiovascular Risk Factors and Association With Socioeconomic Status in Canada, 2005-2016. <i>JAMA Network Open</i> , 2021, 4, e2121443.	5.9	11
14	The effect of periprocedural beta blocker withdrawal on arrhythmic risk following transcatheter aortic valve replacement. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1361-1366.	1.7	10
15	Characterization of a previously unrecognized clinical phenomenon: Delayed shock after cardiac implantable electronic device extraction. <i>Heart Rhythm</i> , 2017, 14, 1552-1558.	0.7	9
16	How to use bipolar and unipolar electrograms for selecting successful ablation sites of ventricular premature contractions. <i>Heart Rhythm</i> , 2022, 19, 1067-1073.	0.7	9
17	Early Referral to Coronary Artery Bypass Grafting Following Acute Coronary Syndrome, Trends and Outcomes from the Acute Coronary Syndrome Israeli Survey (ACSIS) 2000â€“2010. <i>Heart Lung and Circulation</i> , 2018, 27, 175-182.	0.4	8
18	Long-Term Outcomes of Iliofemoral Artery Stents after Transfemoral Aortic Valve Replacement. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1733-1740.	0.5	8

#	ARTICLE	IF	CITATIONS
19	Competing risk analysis of ventricular arrhythmia events in heart failure patients with moderately compromised renal dysfunction. <i>Europace</i> , 2020, 22, 1384-1390.	1.7	8
20	Elevated Admission Potassium Levels and 1-Year and 10-Year Mortality Among Patients With Heart Failure. <i>American Journal of the Medical Sciences</i> , 2017, 354, 268-277.	1.1	7
21	Risk of arrhythmic events after alcohol septal ablation for hypertrophic cardiomyopathy using continuous implantable cardiac monitoring. <i>Heart Rhythm</i> , 2021, 18, 50-56.	0.7	7
22	Use of oral contraceptives in women with congenital long QT syndrome. <i>Heart Rhythm</i> , 2022, 19, 41-48.	0.7	7
23	CHA2DS2-VASc score performance to predict stroke after acute decompensated heart failure with and without reduced ejection fraction. <i>Europace</i> , 2019, 21, 1639-1645.	1.7	6
24	The Association of Body Mass Index and 20-Year All-Cause Mortality Among Patients With Stable Coronary Artery Disease. <i>Heart Lung and Circulation</i> , 2019, 28, 719-726.	0.4	6
25	CHADS2 and CHA2DS2-VASc scores as predictors of platelet reactivity in acute coronary syndrome. <i>Journal of Cardiology</i> , 2021, 77, 375-379.	1.9	6
26	Sex hormones and repolarization dynamics during the menstrual cycle in women with congenital long QT syndrome. <i>Heart Rhythm</i> , 2022, 19, 1532-1540.	0.7	6
27	Sex Differences in the Risk of First and Recurrent Ventricular Tachyarrhythmias Among Patients Receiving an Implantable Cardioverter-Defibrillator for Primary Prevention. <i>JAMA Network Open</i> , 2022, 5, e2217153.	5.9	6
28	Transvenous lead extraction with laser reduces need for femoral approach during the procedure. <i>PLoS ONE</i> , 2019, 14, e0215589.	2.5	5
29	Predictors and outcomes of atrial tachyarrhythmia among patients with implantable defibrillators. <i>Heart Rhythm</i> , 2020, 17, 553-559.	0.7	5
30	Regional and socioeconomic disparities in cardiovascular disease in Canada during 2005-2016: evidence from repeated nationwide cross-sectional surveys. <i>BMJ Global Health</i> , 2021, 6, e006809.	4.7	5
31	Transvenous Lead Extraction in Patients with Cardiac Implantable Device: The Impact of Systemic and Local Infection on Clinical Outcomes- An ESC-EHRA ELECTRa (European Lead Extraction Controlled) Registry Substudy. <i>Biology</i> , 2022, 11, 615.	2.8	5
32	Risk of death without appropriate defibrillator shock in patients with advanced renal dysfunction. <i>Europace</i> , 2019, 21, 459-464.	1.7	4
33	Outcome by Sex in Patients With Long QT Syndrome With an Implantable Cardioverter Defibrillator. <i>Journal of the American Heart Association</i> , 2020, 9, e016398.	3.7	4
34	Circadian variation and seasonal distribution of implantable defibrillator detected new onset atrial fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 1495-1500.	1.2	4
35	Implantable cardioverter-defibrillator programming after first occurrence of ventricular tachycardia in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). <i>Heart Rhythm O2</i> , 2020, 1, 77-82.	1.7	4
36	Predicting the risk of late futile outcome after transcatheter aortic valve implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E695-E702.	1.7	4

#	ARTICLE	IF	CITATIONS
37	Increasing Lesion Dimensions of Bipolar Ablation by Modulating the Surface Area of the Return Electrode. <i>JACC: Clinical Electrophysiology</i> , 2022, 8, 498-510.	3.2	4
38	Cardiac Resynchronization Therapy and Risk of Recurrent Hospitalizations in Patients Without Left Bundle Branch Block. <i>Circulation: Heart Failure</i> , 2020, 13, e006925.	3.9	3
39	Patient selection for wearable cardioverter defibrillator therapy after myocardial infarction: How can we incorporate compliance into decision-making?. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 1019-1021.	1.7	3
40	Systolic Blood Pressure and Risk for Ventricular Arrhythmia in Patients With an Implantable Cardioverter Defibrillator. <i>American Journal of Cardiology</i> , 2021, 143, 74-79.	1.6	3
41	Renal Denervation for Patients With Atrial Fibrillation. <i>Current Cardiology Reports</i> , 2021, 23, 126.	2.9	3
42	Utility of cardiovascular implantable electronic device-derived patient activity to predict clinical outcomes. <i>Heart Rhythm</i> , 2021, 18, 1344-1351.	0.7	3
43	Donor-recipient ethnic mismatching impacts short- and long-term results of heart transplantation. <i>Clinical Transplantation</i> , 2018, 32, e13389.	1.6	2
44	Extending the MADIT-ICD benefit score to heterogenous heart failure populations. <i>European Heart Journal</i> , 2021, 42, 4774-4775.	2.2	2
45	Ethnic Disparity in Mortality Among Ischemic Heart Disease Patients. A-20 Years Outcome Study From Israel. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 661390.	2.4	2
46	Outcomes associated with the high sensitivity cardiac troponin testing in patients presenting with non-cardiovascular disorders. <i>American Journal of Emergency Medicine</i> , 2021, 51, 280-284.	1.6	2
47	Outcomes Associated with Introduction of the 5th Generation High-Sensitivity Cardiac Troponin in Patients Presenting with Cardiovascular Disorders. <i>Journal of Emergency Medicine</i> , 2022, , .	0.7	2
48	Relation of Atrial Premature Complexes During Exercise Stress Testing to the Risk for the Development of Atrial Fibrillation in Patients Undergoing Cardiac Rehabilitation. <i>American Journal of Cardiology</i> , 2018, 122, 395-399.	1.6	1
49	Applicability of the MADIT-CRT Response Score for Prediction of Long-Term Clinical and Arrhythmic Events by QRS Morphology. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008499.	4.8	1
50	High fitness might be associated with the development of new-onset atrial fibrillation in obese non-athletic adults. <i>International Journal of Clinical Practice</i> , 2020, 74, e13638.	1.7	1
51	Risk factors for ventricular tachyarrhythmic events in patients without left bundle branch block who receive cardiac resynchronization therapy. <i>Annals of Noninvasive Electrocardiology</i> , 2021, 26, e12847.	1.1	1
52	Reply to the editor's "Disseminated intravascular coagulation as a cause of shock related to device extraction. <i>Heart Rhythm</i> , 2018, 15, e35.	0.7	0
53	QRS change in heart failure: When is the right time for cardiac resynchronization therapy?. <i>International Journal of Cardiology</i> , 2019, 296, 87-88.	1.7	0
54	The role and outcomes of new supraventricular tachycardia among patients with mild heart failure. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 1099-1104.	1.7	0

#	ARTICLE	IF	CITATIONS
55	Marital Status and Long-Term Outcomes in Mild Heart Failure Patients With an Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy With Defibrillator. <i>American Journal of Cardiology</i> , 2020, 125, 1180-1186.	1.6	0
56	Hospitalization for Heart Failure and Subsequent Ventricular Tachyarrhythmias in Patients With Left Ventricular Dysfunction. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 1099-1107.	3.2	0
57	Post-cardiac Implantable Electronic Devices: Inflammation of the Pocket. Should We Be More Aggressive?. <i>Israel Medical Association Journal</i> , 2018, 20, 539-542.	0.1	0
58	Effect of Left Atrial Enlargement on Success Rates of Catheter Ablation of Atrial Fibrillation in Women. <i>Israel Medical Association Journal</i> , 2019, 21, 13-19.	0.1	0
59	Reduction in Ventricular Tachyarrhythmia Burden in Patients Enrolled in the RAID Trial. <i>JACC: Clinical Electrophysiology</i> , 2022, , .	3.2	0